Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency

被引：9

作者：

Bakacs, Tibor ^{[1
]}

Mehrishi, Jitendra N. ^{[2
,3
]}

机构：

[1] Hungarian Acad Sci, Alfred Renyi Inst Math, Dept Probabil, H-1053 Budapest, Hungary

[2] Univ Cambridge, Cultivated RBC Res Initiat, Cambridge Blood, Umbil Cord Blood Stem Cells Cell Therapy Adults C, Cambridge CB24 9LZ, England

[3] Univ Cambridge, Dept Radiotherapeut, Cambridge CB24 9LZ, England

来源：

IMMUNOBIOLOGY | 2015年 / 220卷 / 05期

关键词：

Anti-CTLA-4; antibody; Ipilimumab; CTLA-4; haploinsufficiency; Targeted immunotherapy; IPILIMUMAB;

D O I：

10.1016/j.imbio.2014.11.019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The inhibitory anti-CTLA-4 antibody, ipilimumab, dramatically improved survival in a subgroup of metastatic melanoma patients. The majority, however, suffered autoimmune-related adverse events (irAEs), sometimes pathognomonic of acute graft-versus-host-disease (GVHD). This implies that the CTLA-4 blockade is not tumor specific. We make a risky but testable prediction: anti-CTLA-4 therapy may have mechanism similar to that occurring in inherited human CTLA-4 haploinsufficiency. If so, a therapeutic paradigm shift is required. The task is not desperately trying to put the genie back in the bottle by immune-suppressive treatments,but harnessing the immense forces liberated by the anti-CTLA-4 antibody blockade by pretargeting or dose adjustment. (C) 2014 Elsevier GmbH. All rights reserved.

引用

页码：624 / 625

页数：2

共 11 条

[1] T cells survey the stability of the self:: A testable hypothesis on the homeostatic role of TCR-MHC interactions [J].

Bakacs, Tibor ;

Mehrishi, Jitendra N. ;

Szabados, Tamas ;

Varga, Laszlo ;

Szabo, Miklos ;

Tusnady, Gabor .

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2007, 144 (02) :171-182

[2] Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy) [J].

Bakacs, Tibor ;

Mehrishi, Jitendra N. ;

Szabo, Miklos ;

Moss, Ralph W. .

PHARMACOLOGICAL RESEARCH, 2012, 66 (02) :192-197

[3] CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].

Bashey, Asad ;

Medina, Bridget ;

Corringham, Sue ;

Pasek, Mildred ;

Carrier, Ewa ;

Vrooman, Linda ;

Lowy, Israel ;

Solomon, Scott R. ;

Morris, Lawrence E. ;

Holland, H. Kent ;

Mason, James R. ;

Alyea, Edwin P. ;

Soiffer, Robert J. ;

Ball, Edward D. .

BLOOD, 2009, 113 (07) :1581-1588

[4] Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe" [J].

Curran, Michael A. ;

Callahan, Margaret K. ;

Subudhi, Sumit K. ;

Allison, James P. .

IMMUNOBIOLOGY, 2012, 217 (06) :590-592

[5] CAR-T cell therapy seeks strategies to harness cytokine storm [J].

DeFrancesco, Laura .

NATURE BIOTECHNOLOGY, 2014, 32 (07) :604-604

[6] Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer [J].

Graziani, Grazia ;

Tentori, Lucio ;

Navarra, Pierluigi .

PHARMACOLOGICAL RESEARCH, 2012, 65 (01) :9-22

[7] Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 [J].

Kuehn, Hye Sun ;

Ouyang, Weiming ;

Lo, Bernice ;

Deenick, Elissa K. ;

Niemela, Julie E. ;

Avery, Danielle T. ;

Schickel, Jean-Nicolas ;

Tran, Dat Q. ;

Stoddard, Jennifer ;

Zhang, Yu ;

Frucht, David M. ;

Dumitriu, Bogdan ;

Scheinberg, Phillip ;

Folio, Les R. ;

Frein, Cathleen A. ;

Price, Susan ;

Koh, Christopher ;

Heller, Theo ;

Seroogy, Christine M. ;

Huttenlocher, Anna ;

Rao, V. Koneti ;

Su, Helen C. ;

Kleiner, David ;

Notarangelo, Luigi D. ;

Rampertaap, Yajesh ;

Olivier, Kenneth N. ;

McElwee, Joshua ;

Hughes, Jason ;

Pittaluga, Stefania ;

Oliveira, Joao B. ;

Meffre, Eric ;

Fleisher, Thomas A. ;

Holland, Steven M. ;

Lenardo, Michael J. ;

Tangye, Stuart G. ;

Uzel, Gulbu .

SCIENCE, 2014, 345 (6204) :1623-1627

[8] Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response [J].

Kvistborg, Pia ;

Philips, Daisy ;

Kelderman, Sander ;

Hageman, Lois ;

Ottensmeier, Christian ;

Joseph-Pietras, Deborah ;

Welters, Marij J. P. ;

van der Burg, Sjoerd ;

Kapiteijn, Ellen ;

Michielin, Olivier ;

Romano, Emanuela ;

Linnemann, Carsten ;

Speiser, Daniel ;

Blank, Christian ;

Haanen, John B. ;

Schumacher, Ton N. .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (254)

[9] Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity [J].

Slavin, Shimon ;

Moss, Ralph W. ;

Bakacs, Tibor .

PHARMACOLOGICAL RESEARCH, 2014, 79 :9-12

[10] The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network [J].

Voskens, Caroline J. ;

Goldinger, Simone M. ;

Loquai, Carmen ;

Robert, Caroline ;

Kaehler, Katharina C. ;

Berking, Carola ;

Bergmann, Tanja ;

Bockmeyer, Clemens L. ;

Eigentler, Thomas ;

Fluck, Michael ;

Garbe, Claus ;

Gutzmer, Ralf ;

Grabbe, Stephan ;

Hauschild, Axel ;

Hein, Ruediger ;

Hundorfean, Gheorghe ;

Justich, Armin ;

Keller, Ullrich ;

Klein, Christina ;

Mateus, Christine ;

Mohr, Peter ;

Paetzold, Sylvie ;

Satzger, Imke ;

Schadendorf, Dirk ;

Schlaeppi, Marc ;

Schuler, Gerold ;

Schuler-Thurner, Beatrice ;

Trefzer, Uwe ;

Ulrich, Jens ;

Vaubel, Julia ;

von Moos, Roger ;

Weder, Patrik ;

Wilhelm, Tabea ;

Goeppner, Daniela ;

Dummer, Reinhard ;

Heinzerling, Lucie M. .

PLOS ONE, 2013, 8 (01)

← 1 2 →